Available on demand on cable, CNBC.com, CNBC+, CNBC Pro or anywhere you stream CNBC. In this article These leadership takeaways are part of a new primetime series, CNBC Leaders Playbook, premiering ...

From technological advances and geopolitical changes to workplace culture shifts and market pressures, 2025 has been a year of change, uncertainty, and disruption. I’m Gwen Moran, and for nearly three ...

Many partners assume that if they love each other enough, cooperation will simply happen in its own time. But research, in recent years, has introduced an important clarification: Good relationships ...

Scottie Scheffler just wrapped up another dominant season, claiming his fourth consecutive PGA TOUR Player of the Year award. Four straight years as the best player on tour. He's now won this ...

At a time when celebrity routines often promote extreme diets and strict workouts, Oscar-winning actor Jennifer Lawrence stands out for her refreshing approach to fitness and body image. Her fitness ...

More ex-pupils have now come forward to Channel 4 News following our investigation into Mike Thompson, who wrote the bestselling novel since adapted into a hit film, writes Cathy Newman. Police have ...

Intentionality has become the defining trait of AI maturity as CIOs across industries learn to turn enthusiasm into structure, and pilots into platforms. Most enterprises have been dabbling in AI for ...

BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, ...

Reprogrammed Interchange LLC, a ten percent owner of Vor Biopharma Inc. (NASDAQ:VOR), reported selling shares of common stock in multiple transactions on October 8th and 9th, 2025, for a total value ...

A Channel 4 News investigation can reveal shocking allegations against Mike Thompson, who authored the memoir The Penguin Lessons under the pen name ‘Tom Michell’, adapted into the 2024 feature film ...

Vor Biopharma (NASDAQ:VOR) has been upgraded to Buy from Hold at Stifel as confidence in the company’s long-term potential has grown following prospects for its lead asset, telitacicept. The shares of ...